AstraZeneca Rides Wave Of Crestor Data; Is Pfizer Facing Lipitor Wipeout?
Executive Summary
Wall Street appears to feel that AstraZeneca has weathered the run up to the launch of generic statins far better than Pfizer
You may also be interested in...
Bristol Sprycel Clears FDA As First Second-Line Leukemia Agent
Bristol-Myers Squibb will be required to submit follow-up data from ongoing clinical trials to convert the accelerated approval of Sprycel for chronic myeloid leukemia to full approval, FDA said after clearing dasatinib June 28
Merck Pushes Discount Zocor; Health Plans Are Wary, But Pfizer Is Concerned
The mixed response to Merck's efforts to reach rebate agreements with health plans to place brand Zocor on the lowest cost-sharing tiers of their formularies suggests it is unlikely such a strategy would be broadly adopted by brand firms going forward
Pharma Investors Need To Look Long Term, Especially With Pfizer – McKinnell
Pharmaceutical industry investors should be less concerned about short-term performance in a sector with an extended business cycle, Pfizer CEO Hank McKinnell said June 13